Tangible Impact
Our support enabled the client to clearly demonstrate the significant cost-saving potential of their innovative tumour-grading technology. By implementing our comprehensive Budgetary Impact Analysis, we highlighted the potential for substantial savings over a 5-year period when the technology is introduced as a substitute for the existing care pathway. This not only bolstered the product’s value proposition but also provided a tangible framework for demonstrating its economic benefits to key NHS decision-makers, offering a strong case for adoption.
“The work by HTE was invaluable in understanding the budgetary impact of the Tumour Profiling Test. The model allowed us to identify the target patient subgroup of most interest, and for that subgroup, establish the value proposition of our innovation.” Hemmel Amrania, CEO of Digistain
Assessing the Challenge
The client had developed a revolutionary breast cancer treatment technology designed to reduce unnecessary chemotherapy treatments by better stratifying patients based on their risk of cancer recurrence. The challenge was to understand how this innovation would fit within the NHS’s existing care pathways, quantify its impact on user budgets, and assess how it could be implemented at scale to optimize treatment outcomes while reducing costs.
Tailored Approach
To address this, we worked closely with the client to define two implementation scenarios: one where the technology would act as an adjunct to the existing care pathway and another where it would replace the current treatment model. We conducted an in-depth literature review and built a decision analytical model combining decision trees and Markov models to simulate the budgetary impact over five years. Our model incorporated probabilistic sensitivity analysis to account for uncertainties, offering the client a detailed understanding of the cost-effectiveness of the innovation for different patient subgroups.
